# v3.10

## Related releases

## Data changes
Alteration:
BRAF V600M, Oncogenicity Updated
	 New: Inconclusive
	 Old: Likely
BRCA1 L147F, Oncogenicity Updated
	 Old: Likely Neutral
ERBB2 D277H, Mutation Effect Description Updated
KIT X550_splice, Mutation Effect Description Updated
MAP2K1 P105_I107delinsS, Mutation Effect Description Updated
MAP2K1 P105_I107del, Mutation Effect Description Updated
MAP2K1 E41_F53del, Mutation Effect Description Updated
MAP2K1 E41_L54del, Mutation Effect Description Updated
MAP2K1 L42F, Mutation Effect Description Updated
MAP2K1 L42_K57del, Mutation Effect Description Updated
MAP2K1 L50_E51insI, Mutation Effect Description Updated
MAP2K1 F53I, Mutation Effect Description Updated
MAP2K1 F53V, Mutation Effect Description Updated
MAP2K1 F53_Q58delinsL, Mutation Effect Description Updated
MAP2K1 T55P, Mutation Effect Description Updated
MAP2K1 Q56_G61delinsR, Mutation Effect Description Updated
MAP2K1 K57_V60delinsN, Mutation Effect Description Updated
MAP2K1 L98_I99del, Mutation Effect Description Updated
MAP2K1 K57_G61del, Mutation Effect Description Updated
MAP2K1 I99_H100del, Mutation Effect Description Updated
MAP2K1 L98_I103delinsES, Mutation Effect Description Updated
MAP2K1 H100_I103delinsPL, Mutation Effect Description Updated
MAP2K1 H100_L101del, Mutation Effect Description Updated
MAP2K1 K104_P105del, Mutation Effect Description Updated
MAP2K1 I103M, Mutation Effect Description Updated
MAP2K1 L101_E102del, Mutation Effect Description Updated
MAP2K1 A106_I107del, Mutation Effect Description Updated
MAP2K1 L105_I107delinsL, Mutation Effect Description Updated
MAP2K1 L105_A106del, Mutation Effect Description Updated
MAP2K1 Q110_I111del, Mutation Effect Description Updated
MAP2K1 N109_Q110del, Mutation Effect Description Updated
MAP2K1 R108_N109del, Mutation Effect Description Updated
MAP2K1 I107_R108del, Mutation Effect Description Updated
MAP2K1 R113_E114del, Mutation Effect Description Updated
MAP2K1 I112_R113del, Mutation Effect Description Updated
MAP2K1 I111_I112del, Mutation Effect Description Updated
MAP2K1 E114_L115del, Mutation Effect Description Updated
MAP2K1 P124R, Mutation Effect Description Updated
MAP2K1 N122D, Mutation Effect Description Updated
MAP2K1 H119Q, Mutation Effect Description Updated
MAP2K1 H119Y, Mutation Effect Description Updated
MAP2K1 E203Q, Mutation Effect Description Updated
MAP2K1 E203V, Mutation Effect Description Updated
MAP2K1 E203R, Mutation Effect Description Updated
MAP2K2 Y134H, Mutation Effect Description Updated
MAP2K2 L46_E55del, Mutation Effect Description Updated
MAP2K2 K61T, Mutation Effect Description Updated
MAP2K2 V64D, Mutation Effect Description Updated
MAP2K2 D71N, Mutation Effect Description Updated
MAP2K2 I107N, Mutation Effect Description Updated
MAP2K2 H123Q, Mutation Effect Description Updated
MAP2K2 P128L, Mutation Effect Description Updated
MAP2K2 G132D, Mutation Effect Description Updated
MAP2K2 Y134C, Mutation Effect Description Updated
MAP2K2 L181M, Mutation Effect Description Updated
MTOR A1428T, Mutation Effect Description Updated
MTOR V2006F, Mutation Effect Description Updated
MTOR L2172M, Mutation Effect Description Updated
MTOR A2210P, Mutation Effect Description Updated
MTOR L2216P, Mutation Effect Description Updated
MTOR R2217W, Mutation Effect Description Updated
MTOR A2226S, Mutation Effect Description Updated
MTOR S2231W, Mutation Effect Description Updated
MTOR T2232I, Mutation Effect Description Updated
PIK3CA E970K, Mutation Effect Description Updated
RET C609Y, Mutation Effect Description Updated
RET I852M, Mutation Effect Description Updated
RET D631_L633delinsE, Mutation Effect Description Updated
STK11 Oncogenic Mutations Added

Evidence:
ABL1 T315I, Chronic Myelogenous Leukemia, Imatinib, Dasatinib, Nilotinib, Bosutinib  Updated
ABL1 T315I, B-Lymphoblastic Leukemia/Lymphoma, Imatinib, Dasatinib, Nilotinib, Bosutinib  Updated
ABL1 Y253H, E255K, E255V, F359V, F359C, F359I (Dasatinib), B-Lymphoblastic Leukemia/Lymphoma, Dasatinib  Updated
ABL1 Y253H, E255K, E255V, F359V, F359C, F359I (Dasatinib), Chronic Myelogenous Leukemia, Dasatinib  Updated
ABL1 V299L, T315A, F317L, F317V, F317I, F317C (Nilotinib), Chronic Myelogenous Leukemia, Nilotinib  Updated
ABL1 F317V, F317I, F317C, F317L, T315A, V299L (R1 Dasatinib), B-Lymphoblastic Leukemia/Lymphoma, Dasatinib  Updated
ABL1 E255K, E255V, F359C, F359I, F359V, Y253H, G250E (R1 Nilotinib), Chronic Myelogenous Leukemia, Nilotinib  Updated
ABL1 E255K, E255V, F359C, F359I, F359V, Y253H, G250E (R1 Nilotinib), B-Lymphoblastic Leukemia/Lymphoma, Nilotinib  Updated
ABL1 V299L, G250E, F317V, F317I, F317C, F317L, T315A, E255K, E255V, F359C, F359I, F359V, Y253H (R1 Imatinib), Chronic Myelogenous Leukemia, Imatinib  Updated
ABL1 V299L, G250E, F317V, F317I, F317C, F317L, T315A, E255K, E255V, F359C, F359I, F359V, Y253H (R1 Imatinib), B-Lymphoblastic Leukemia/Lymphoma, Imatinib  Updated
ABL1 BCR-ABL1 Fusion, B-Lymphoblastic Leukemia/Lymphoma, Bosutinib  Updated
ARAF Oncogenic Mutations, Erdheim-Chester Disease, Cobimetinib, Trametinib  Updated
ARAF Oncogenic Mutations, Langerhans Cell Histiocytosis, Cobimetinib, Trametinib  Updated
ARAF Oncogenic Mutations, Rosai-Dorfman Disease, Cobimetinib, Trametinib  Updated
ARID1A Truncating Mutations, All Solid Tumors, Tazemetostat  Updated
ARID1A Truncating Mutations, All Solid Tumors, PLX2853  Updated
BRCA1 Oncogenic Mutations, Acinar Cell Carcinoma of the Pancreas, Pancreatic Adenocarcinoma, Olaparib  Updated
BRCA2 Oncogenic Mutations, Acinar Cell Carcinoma of the Pancreas, Pancreatic Adenocarcinoma, Olaparib  Updated
BTK C481S, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Ibrutinib  Updated
BTK C481F, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Ibrutinib  Updated
BTK C481Y, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Ibrutinib  Updated
BTK C481R, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Ibrutinib  Updated
BTK T474I, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Ibrutinib  Updated
BTK T474S, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Ibrutinib  Updated
BTK T316A, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Ibrutinib  Updated
EGFR Kinase Domain Duplication, Non-Small Cell Lung Cancer, Gefitinib  Updated
EGFR 762_823ins [Exon 20 insertion], Non-Small Cell Lung Cancer, Poziotinib  Updated
FLT3 572_630ins [Internal tandem duplication], Acute Myeloid Leukemia, Crenolanib  Updated
KRAS Oncogenic Mutations, All Solid Tumors, Trametinib, Cobimetinib, Binimetinib  Updated
KRAS Oncogenic Mutations, Erdheim-Chester Disease, Cobimetinib, Trametinib  Updated
KRAS Oncogenic Mutations, Langerhans Cell Histiocytosis, Cobimetinib, Trametinib  Updated
KRAS Oncogenic Mutations, Rosai-Dorfman Disease, Cobimetinib, Trametinib  Updated
MAP2K1 Oncogenic Mutations, Langerhans Cell Histiocytosis, Cobimetinib, Trametinib  Updated
MAP2K1 Oncogenic Mutations, Erdheim-Chester Disease, Tumor Type Summary Updated
MAP2K1 Oncogenic Mutations, Erdheim-Chester Disease, Cobimetinib, Trametinib  Updated
MAP2K1 Oncogenic Mutations, Rosai-Dorfman Disease, Cobimetinib, Trametinib  Updated
MAP2K2 Oncogenic Mutations, Erdheim-Chester Disease, Cobimetinib, Trametinib  Updated
MAP2K2 Oncogenic Mutations, Langerhans Cell Histiocytosis, Cobimetinib, Trametinib  Updated
MAP2K2 Oncogenic Mutations, Rosai-Dorfman Disease, Cobimetinib, Trametinib  Updated
MTOR L2427Q, L2209V, Renal Cell Carcinoma, Temsirolimus  Updated
MTOR Q2223K, Renal Cell Carcinoma, Everolimus  Updated
NRAS Oncogenic Mutations, Erdheim-Chester Disease, Cobimetinib, Trametinib  Updated
NRAS Oncogenic Mutations, Langerhans Cell Histiocytosis, Cobimetinib, Trametinib  Updated
NRAS Oncogenic Mutations, Rosai-Dorfman Disease, Cobimetinib, Trametinib  Updated
NRG1 Fusions, All Solid Tumors, Zenocutuzumab  Updated
PDGFRA Oncogenic Mutations, Gastrointestinal Stromal Tumor, Sunitinib  Updated
PDGFRA Oncogenic Mutations, Gastrointestinal Stromal Tumor, Regorafenib  Updated
RAF1 Oncogenic Mutations, Erdheim-Chester Disease, Cobimetinib, Trametinib  Updated
RAF1 Oncogenic Mutations, Langerhans Cell Histiocytosis, Cobimetinib, Trametinib  Updated
RAF1 Oncogenic Mutations, Rosai-Dorfman Disease, Cobimetinib, Trametinib  Updated
RET Fusions, Non-Small Cell Lung Cancer, Vandetanib  Updated